Invesco DB Commodity Index Tracking Fund vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.93 (market cap $1.92B), while Nuvation Bio Inc. Class A Common Stock trades at $5.07 (market cap $1.74B). The key difference: Invesco DB Commodity Index Tracking Fund and Nuvation Bio Inc. Class A Common Stock are close in size by market cap, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| DBC | NUVB | |
|---|---|---|
Market Cap | $1.92B | $1.74B |
Volume | 1,375,556 | 9,289,619 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $9.54 |
52-Week Low | $22.07 | $3.41 |
Typical Hold Time | 60 Days | 1 Days |
Enterprise Value | — | $1.33B |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →